Merck Says FDA Accepts Application For KEYTRUDA (pembrolizumab) Plus Chemotherapy As Treatment For Advanced Or Unresectable Biliary Tract Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Merck's sBLA for KEYTRUDA in combination with chemotherapy for the treatment of advanced or unresectable biliary tract cancer. The application is based on the KEYNOTE-966 trial, which showed a significant improvement in overall survival compared to chemotherapy alone.
June 08, 2023 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA sBLA has been accepted by the FDA for the treatment of advanced biliary tract cancer, potentially expanding the drug's market.
The FDA's acceptance of Merck's sBLA for KEYTRUDA in combination with chemotherapy for advanced biliary tract cancer treatment is a positive development for the company. This could potentially expand the market for KEYTRUDA, leading to increased revenues and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100